Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
复制标题
DOI：
10.1056/nejmoa1112802
复制
发表时间：
2012-12-20
影响因子：
158.5
通讯作者：
Martini, Alberto
中科院分区：
文献类型：
--
作者：
De Benedetti, Fabrizio;Brunner, Hermine I.;Martini, Alberto
背景：系统性幼年特发性关节炎(JIA)是JIA中最严重的亚型，治疗选择有限。白介素6在系统性JIA中起致病作用。方法：我们随机将112名2至17岁的系统性JIA儿童随机分配到抗IL-6受体抗体tocilizumab(如果体重=30 kg或12 mg/kg，体重=30 kg或12 mg/kg，持续6个月，且对非类固醇抗炎药和糖皮质激素反应不佳)。
BACKGROUNDSystemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA.METHODSWe randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of >= 6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was >= 30 kg or 12 mg per kilogram if the weight was